Metabolic syndrome in patients with prostate cancer

Sao Paulo Medical Journal

Volumn 126, Issue 5, 2008, Pages 274-278

  De Santana, Iúri Amorim ^a,c   Moura, Gustavo Souza ^a   Vieira, Nivaldo Farias ^b   Cipolotti, Rosana ^a  

^a FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^b Fundação de Beneficência Hospital e Cirurgia   (Brazil)

^c NONE   (Brazil)

Author keywords

Hyperglycemia; Metabolic syndrome X; Obesity; Prostate cancer; Prostate specific antigen

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRAZIL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; INSULIN RESISTANCE; LEAN BODY WEIGHT; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSTATE CANCER; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

EID: 58149465390     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802008000500006     Document Type: Article

References (38)

1. Brasil. Ministério da Saúde. Secretaria Nacional de Assistência à Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância - Conprev. Câncer da Próstata: consenso. Rio de Janeiro: INCA; 2002. Available from: http://bvsms.saude.gov.br/ bvs/publicacoes/inca/manual_prostata.pdf. Accessed in 2008 (Jul 16).
2. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107(10):2361-7.
3. Sociedade Brasileira de Hipertensão. Conceituação, epidemiologia e diagnóstico. Revista da Sociedade Brasileira de Hipertensão. 2004;7(4):130-1. Available from: http://www.sbh.org.br/novo/arquivos/documentos/22.pdf. Accessed in 2008 (Aug 12).
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60-7.
5. Oliveira EP, Souza MLA, Lima MDA. Prevalência de síndrome metabólica em uma área rural do semi-árido baiano. [Prevalence of metabolic syndrome in a semi-arid rural area in Bahia]. Arq Bras Endocrinol Metab. 2006;50(3):456-65.
6. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9.
7. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18):2887-95.
8. Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. Rev Urol. 2001;3(Suppl 2):S31-8.
9. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959-68.
10. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001;4(2):101-5.
11. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989;129(3):511-7.
12. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):557-63.
13. Sox HC. Current controversies in screening: cholesterol, breast cancer, and prostate cancer. Mt Sinai J Med. 1999;66(2):91-101.
14. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000;151(6):541-9.
15. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989-1003.
16. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-93.
17. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome, 2005. Available from: http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf. Accessed in 2008 (Jul 17).
18. Sociedade Brasileira de Hipertensão. V Diretrizes Brasileiras de Hipertensão Arterial. Hipertensão. 2006. Available from: http://www.sbn.org.br/Diretrizes/ V_Diretrizes_Brasileiras_de_Hipertensao_Arterial.pdf. Accessed in 2008 (Jul 17).
19. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-8.
20. Sociedade Brasileira de Análises Clínicas. Secretarias Técnicas. Comitê Brasileiro de Análises Clínicas e Diagnóstico in vitro, 1998. Normas desenvolvidas pelo CB-36. Available from: http://www.sbac.org.br/pt/ conteudos/secretarias_tecnicas/abnt_cb_36.htm#2. Accessed in 2008 (Aug 13).
21. Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997;6(11):863-73.
22. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, 1999. Available from: http://whqlibdoc.who.int/hq/1999/ WHO_NCD_NCS_99.2.pdf. Accessed in 2008 (Jul 17).
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
24. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer. 1997;73(5):634-8.
25. Irani J, Lefebvre O, Murat F, Dahmani L, Doré B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int. 2003;91(6):482-4.
26. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11(8):534-42.
27. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer. 2003;89(7):1237-42.
28. Severson RK, Grove JS, Nomura AM, Stemmermann GN. Body mass and prostatic cancer: a prospective study. BMJ. 1988;297(6650):713-5.
29. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1417-21.
30. Maturo G, Vespasiani G, Mohamed EI, et al. Evaluating body composition of Italian prostate cancer patients without metastases. Acta Diabetol. 2003;40(Suppl 1):S168-70.
31. Alexopoulos CG, Blatsios B, Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer. 1987;60(12):3065-70.
32. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000;30(3):141-5.
33. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989;49(7):1857-60.
34. Fournier DB, Erdman JW Jr, Gordon GB. Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev. 1998;7(11):1055-65.
35. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12(7):665-8.
36. Lee IM, Sesso HD, Chen JJ, Paffenbarger RS Jr. Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev. 2001;23(1):132-7.
37. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132(11 Suppl):3456S-64S.
38. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol. 2004;159(8):740-9.